Arctic Bioscience - New positive data showing anti-inflammatory effects of phospholipid esters from herring roe in immune cells

26 Jun 2024 10:00 CEST

Arctic Bioscience are today presenting a new data on anti-inflammatory cellular
functions of herring roe oil at the 9th European Workshop on Lipid Mediators in
Edinburgh, UK.

"We are very pleased to announce new positive data on the anti-inflammatory
properties related to our investigational medicine, HRO350. The data show an
effect on cells which may also have benefit in other inflammatory diseases,
which we will explore further", says CEO Christer L. Valderhaug.

"These data are important because they illuminate a mechanism of action of
HRO350, which is currently being tested in a phase 2b clinical trial for mild-to
-moderate psoriasis. Scientifically, this is state-of-the-art lipidomics, and we
have collaborated with a key international research group in this field. We are
also proud that this research has been conducted in Norway, with cellular
researchers at Møreforsking", says Medical Director Runhild Gammelsæter.

The HeROPA clinical trial on HRO350 with the active substance Phospholipid
Esters from Herring Roe (PeHeRo) is ongoing in mild-to-moderate psoriasis, with
planned read-out fall 2024.

These new data on human primary immune cells show that Phospholipid Esters from
Herring Roe promotes biosynthesis of specialized pro-resolving mediators (SPMs)
that are involved in anti-inflammatory activities. This mode of action can be a
promising treatment modality in inflammatory conditions, including psoriasis,
and supports an anti-inflammatory action of the investigational medicinal
product HRO350. These data support previously published effects on inflammatory
markers in psoriasis (Petrovic 2023).

"Our chemists in the R&D department have been working on this research project
for three years, and we are very excited to see the effects of the extracts we
have developed in our lab", says CTO Daniele Mancinelli.

The study was conducted in collaboration with Møreforsking and was supported
with a grant from the Norwegian Research Council (project nr. 327953, Properties
of phospholipids from Herring Roe in Psoriasis).

Reference: Ringheim-Bakka T, Mildenberger J, Dalli J, Saliani A, Petrucelli F,
Busygina M, Mancinelli D, Gammelsæter R. "Phospholipid Esters from Herring Roe
promotes SPM biosynthesis in human monocyte-derived macrophages with
implications for the treatment of psoriasis". Poster at the 9th European
Workshop on Lipid Mediators, June 26-28th, 2024.

The poster will be made available on the IR tab on the company's webpage.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

For further information, please contact:

Christer L. Valderhaug

CEO

Mobile: +47 920 84 601

Email: christer@arctic-bioscience.com

About Arctic Bioscience

Arctic Bioscience is a biotech company developing and commercializing
pharmaceutical and nutraceutical products based on unique bioactive marine
compounds.

The company is developing HRO350 - a novel oral drug candidate. HRO350 is being
developed for treatment of patients with mild-to-moderate psoriasis. This is a
large patient group in need of new effective medicines with beneficial safety
profile.

Nutraceuticals from Arctic Bioscience are sold globally as bulk ingredients as
well as finished goods under the ROMEGA® brand.

Arctic Bioscience is led by a highly skilled team of talents with diverse and
highly relevant background.

More information:
Access the news on Oslo Bors NewsWeb site